Se espera que el mercado de la terapia con células madre crezca de 2.278,49 millones de dólares en 2022 a 6.206,89 millones de dólares en 2028; se estima que crecerá a una tasa compuesta anual del 18,2 % entre 2022 y 2028.
Las células madre son células corporales preliminares a partir de las cuales se generan todas las demás células con funciones especializadas. En un ambiente controlado en el cuerpo o en un laboratorio clínico, estas células se dividen para formar más células, llamadas células hijas. Con el advenimiento de la ciencia de la salud moderna, se ha demostrado que estas células desempeñan un papel importante en la comprensión de la aparición de enfermedades, la generación de medicinas regenerativas avanzadas y el descubrimiento de otros fármacos. Las células madre se forman en embriones, médula ósea, grasas corporales y sangre del cordón umbilical, entre otros.
Perspectivas estratégicas
Perspectivas del mercado
Aumento de lo orgánico e inorgánico Estrategias de los actores clave
Los actores clave del mercado están adoptando diversas estrategias orgánicas e inorgánicas, incluidas fusiones y adquisiciones, expansiones y lanzamientos de nuevos productos, para seguir siendo competitivos en el mercado.
- En octubre de 2022, Medipost (CEO Won-Il Oh) anunció el lanzamiento de su negocio de Organización de Fabricación y Desarrollo por Contrato (CDMO) para productos de terapia celular y génica en Corea. La compañía anunció que sus nuevas instalaciones GMP albergarán 10 salas blancas e instalaciones de producción equipadas con equipos actualizados exclusivamente para CDMO.
- En diciembre de 2019, Lineage Cell Therapeutics y AgeX Therapeutics, en asociación, registraron una marca en EE. UU. patente para el método de generación de células madre pluripotentes inducidas.
- En junio de 2021, Allogene Therapeutics, Inc. anunció que la Administración de Medicamentos y Alimentos de EE. UU. (FDA) otorgó la designación Fast Track a ALLO-605, la compañía&rsquo La terapia AlloCAR T de próxima generación dirigida a BCMA para el tratamiento del mieloma múltiple en recaída o refractario. La FDA otorgó la designación Fast Track basándose en el potencial de ALLO-605 para abordar la necesidad insatisfecha de pacientes que han fracasado con otras terapias estándar para el mieloma múltiple.
Por lo tanto, muchas estrategias orgánicas e inorgánicas en el El mercado de terapia con células madre permite a los profesionales de la salud brindar mejores servicios.
regiones lucrativas en el mercado de terapia con células madre
La terapia con células madre ha sido ampliamente investigada en todo el mundo. Las células madre se utilizan principalmente para reemplazar células moribundas y reconstruir tejidos dañados. Basándose en los resultados de una extensa investigación con células madre realizada hasta ahora, muchos científicos han afirmado que estas células probablemente podrían utilizarse para generar curas y tratamientos para enfermedades como el cáncer y las enfermedades cardiovasculares. Las terapias con células madre recientemente desarrolladas implican reemplazar las células que causan enfermedades con células madre. Muchos tratamientos potenciales que involucran células madre se encuentran en diferentes fases de ensayos clínicos. La FDA también aprobó algunas terapias con células madre involucradas en el tratamiento de complicaciones relacionadas con los trasplantes de células madre. En septiembre de 2021, la Administración de Medicamentos y Alimentos de EE. UU. (FDA) anunció la aprobación de "Ruxolitinib" para el tratamiento de la "enfermedad de injerto contra huésped" (EICH) en pacientes de 12 años o más. Ruxolitinib proporciona una nueva esperanza a un paciente que sufre complicaciones mortales asociadas con los trasplantes de células madre.
Los investigadores están investigando más a fondo el uso de la terapia con células madre en el tratamiento de trastornos autoinmunes. Por ejemplo, las células madre pueden convertirse en células de órganos dañados y se utilizan en el tratamiento de enfermedades autoinmunes. El tratamiento se lleva a cabo utilizando células madre mesenquimales o células madre fetales. Las células madre hematopoyéticas se utilizan actualmente para tratar más de 80 afecciones médicas, incluidas enfermedades del sistema inmunológico; trastornos de la sangre; desórdenes neurológicos; desordenes metabólicos; desordenes genéticos; y tipos de cáncer como leucemia y linfoma.
Type Insights
Según el tipo, el mercado de la terapia con células madre se segmenta en terapia con células madre adultas, terapia con células madre pluripotentes inducidas y terapia con células madre embrionarias. terapia celular y otras terapias con células madre. El segmento de terapia con células madre adultas tuvo la mayor participación de mercado en 2021. Sin embargo, se prevé que el segmento de terapia con células madre pluripotentes inducidas registre la CAGR más alta durante el período de pronóstico (2022-2028).
Información sobre el tratamiento< /h3>
Según el tratamiento, el mercado mundial de terapia con células madre se divide en alogénicas y autólogas. El segmento alogénico tuvo la mayor participación de mercado de terapia con células madre en 2021. Además, se espera que el segmento autólogo crezca al CAGR más alto durante el período de pronóstico.
Application Insights
En términos De aplicación, el mercado de la terapia con células madre se divide en musculoesquelético, dermatología, cardiología, descubrimiento y desarrollo de fármacos, y otras aplicaciones. El segmento de descubrimiento y desarrollo de fármacos tuvo la mayor participación de mercado en 2021 y se espera que registre la CAGR más alta durante el período de pronóstico.
Mercado de terapia con células madre, por tipo: 2021 y 2028
Perspectivas del usuario final
Según el usuario final, el mercado de la terapia con células madre se divide en académico &erio; institutos de investigación y hospitales & clínicas. Lo académico y lo académico; El segmento de institutos de investigación tuvo una mayor participación de mercado en 2021, y se espera que el mismo segmento registre una CAGR más alta en el mercado durante el período de pronóstico (2022-2028).
Empresas en el mercado de terapia con células madre adoptar principalmente estrategias inorgánicas como fusiones y adquisiciones. A continuación se enumeran algunos de los avances clave recientes en el mercado.
- En junio de 2021, la USFDA otorgó la designación Fast Track a ALLO-605, la próxima generación. Terapia AlloCAR T ofrecida por Allogene Therapeutics, Inc., dirigida a BCMA para el tratamiento del mieloma múltiple en recaída o refractario. La designación se otorgó sobre la base del potencial de ALLO-605 para abordar las necesidades insatisfechas de los pacientes que no respondieron a otras terapias estándar para el mieloma múltiple.
- En junio de 2021, MEDIPOST anunció que el La empresa ha ampliado las instalaciones de producción de sus productos de células madre para la osteoartritis de rodilla, CARTISTEM y SMUP-IA-01, y comenzará a prepararse para la certificación GMP (Buenas prácticas de fabricación).
- En septiembre de 2022, Caladrius Biosciences , Inc. y Cend Therapeutics, Inc. anunciaron que la fusión propuesta de las dos compañías se cerró luego de la aprobación de Caladrius&rsquo. accionistas el 13 de septiembre de 2022. La empresa fusionada operará como Lisata Therapeutics, Inc. y se centrará principalmente en el avance de sus candidatos a productos tecnológicos de la plataforma CendR en una variedad de indicaciones oncológicas, además de Caladrius’ programas de desarrollo existentes.
- En marzo de 2019, BioTime, Inc adquirió Asterias Biotherapeutics, Inc., que se dedica a medicamentos regenerativos para consolidar su cartera de productos de terapias con células madre.
Perfiles de la empresa
- MEDIPOST
- Pharmicell Co., Inc.
- RichSource
- BioTime, Inc.
- Mesoblast Limited
- Holostem Terapie Avanzate Srl
- US Stem Cell, Inc.
- Caladrius Biosciences, Inc.
- TiGenix NV
- AlloSource
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
Stem cells are preliminary body cells from which all other cells with specialized functions are generated. Under controlled environment in the body or a clinical laboratory, these cells divide to form more cells called daughter cells. Due to the advent of modern health science, these cells play a major role in understanding the occurrence of diseases, generation of advanced regenerative medicines, and drug discovery. There are certain sources such as embryo, bone marrow, body fats, and umbilical cord blood amongst others, where stem cells are generated.
Increasing research activities related to stem cell therapy for effective disease management and growing prevalence of cancer are the most significant factors responsible for the overall market growth.
Based on type segment, the adult stem cell therapy segment took the forefront leaders in the worldwide market by accounting largest share in 2021 and is expected to continue to do so till the forecast period.
Based on the treatment, allogenic segment took the forefront leaders in the worldwide market by accounting largest share in 2021.
Academic & Research institutes segment dominated the global stem cell therapy market and accounted for the largest market share during the forecast period of 2022-2028.
MEDIPOST, RichSource, BioTime, Inc., Mesoblast Limited, Holostem Terapie Avanzate Srl, U.S. Stem Cell, Inc., TiGenix NV, AlloSource, NuVasive Inc, JCR Pharmaceuticals Co. Ltd. and among others are among the leading companies operating in the stem cell therapy market.
Global stem cell therapy market is segmented by region into North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America.
The List of Companies - Stem Cell Therapy Market
- MEDIPOST
- RichSource
- BioTime, Inc.
- Mesoblast Limited
- Holostem Terapie Avanzate Srl
- U.S. Stem Cell, Inc.
- TiGenix NV
- AlloSource
- NuVasive Inc
- JCR Pharmaceuticals Co. Ltd.
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Related Reports
Feb 2023
Bioprocessing Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product (Instruments, and Consumables and Accessories), Scale of Operation (Commercial Operations and Clinical Operations), Process (Downstream Bioprocess and Upstream Bioprocess), Application (Monoclonal Antibodies, Vaccines, Recombinant Protein, Cell and Gene Therapy, and Others), End User (Biopharmaceutical Companies, Contract Manufacturing Organization, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)
Feb 2023
Bioproduction Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Product (Biologics and Biosimilars, Vaccines, Cell and Gene Therapies, Nucleic Acid Therapeutics, and Others), Application (Rheumatoid Arthritis, Hematological Disorders, Cancer, Diabetes, Cardiovascular Diseases, and Others), Equipment (Upstream Equipment, Downstream Equipment, Bioreactors, and Consumables and Accessories), End User (Biopharmaceutical Companies, Contract Manufacturing Organizations, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Feb 2023
ELISA Diagnostic Test Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Adoption (Human and Veterinary), Test Type (Sandwich ELISA, Indirect ELISA, Competitive ELISA, and Multiple & Portable ELISA), Application (Autoimmune Diseases, Infectious Diseases, Cancer Diagnosis, Protein Quantification, and Others), End User (Hospitals & Diagnostic Centers, Pharmaceutical & Biotechnology Companies, Veterinary Hospitals & Diagnostic Laboratories, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)
Feb 2023
Swine Diagnostics Market
Size and Forecasts (2022 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Product Type [Immunoassays Kits, PCR Kits, Hemagglutination Inhibition (HI), and Others], Sample Type (Blood, Oral Fluids, Nasal Swabs, Tissue Samples, and Others), Disease [African Swine Fever (ASF)/Classical Swine Fever (CSF), Respiratory Diseases, Porcine Circovirus, Porcine Epidemic Diarrhea, Swine Dysentery, and Others], End User (Veterinary Hospitals, Veterinary Clinics, and Other End Users), and Geography
Feb 2023
Microbial Identification Methods Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Method (Genotypic, Phenotypic, and Proteotypic), Type (Bacterial Identification System, Microbial Enumeration System, Bacterial Resistance Identification Systems, Microbiology Analyzer, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and Latin America)
Feb 2023
Biopharmaceuticals Market
Forecast to 2028 - COVID-19 Impact and Global Analysis By Product Type (Monoclonal Antibodies, Recombinant Vaccines, Conventional Vaccines, Recombinant Growth Factors, Purified Proteins, Recombinant Proteins, Recombinant Hormones, Recombinant Enzymes, Cell & Gene Therapies, Cytokines/Interferon/Interleukins, and Others) and Application (Oncology, Inflammatory & Infectious Disease, Autoimmune Disorders, Metabolic Disorders, Hormonal Disorders & Growth Failure, Cardiovascular Diseases, Neurological Diseases, and Others)
Feb 2023
GMP Cell Therapy Consumables Market
Forecast to 2028 - COVID-19 Impact and Global Analysis by Product (Kits, Reagents/Molecular Biology Reagents, Growth Factors/Cytokines and Interleukins, and Others), Cell Therapy (NK Cell Therapy, Stem Cell Therapy, T-Cell Therapy, and Others), Process (Cell Collection and Characterization/Sorting and Separation, Cell Culture and Expansion/Preparation, Cryopreservation, Cell Processing and Formulation, Cell Isolation and Activation, Cell Distribution/Handling, Process Monitoring and Control/Readministration/Quality Assurance, and Others), and End Use (Clinical, Commercial, and Research)